CoChat
Sign Up
Cited by 583

Dendritic cell-derived exosomes for cancer therapy.

Pitt, Jonathan M., André, Fabrice, Amigorena, Sebastian, Soria, Jean-Charles, Eggermont, Alexander, Kroemer, Guido, Zitvogel, Laurence·2016·Journal of Clinical Investigation
DOI 10.1172/jci81137
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci81137

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dendritic cell-derived EVs possess surface adhesion membrane proteins that allow effective targeting and docking to recipient cells.

    “They also possess a variety of surface adhesion membrane proteins, which allow for effective targeting and docking to recipient cells (Pitt et al., 2016).”

    From Engineered Extracellular Vesicles Loaded With miR-124 Attenuate Cocaine-Mediated Activation of Microglia (2020) · cites this paper as Pitt et al., 2016

  • Dendritic cells and their EVs possess MHC-I and MHC-II molecules as well as costimulatory molecules, which interact with immune cells.

    “In addition, dendritic cells and the EVs they produce possess MHC-I and MHC-II molecules as well as costimulatory molecules, which interact with immune cells (Pitt et al., 2016).”

    From Engineered Extracellular Vesicles Loaded With miR-124 Attenuate Cocaine-Mediated Activation of Microglia (2020) · cites this paper as Pitt et al., 2016

  • Dendritic cells and dendritic cell-derived EVs possess MHC-I and MHC-II molecules and costimulatory molecules, facilitating interaction with immune cells.

    “Both dendritic cells as well as EVs derived from dendritic cells are known to possess MHC-I and MHC-II molecules as well as costimulatory molecules, which, in turn, facilitates interaction with immune cells (Pitt et al., 2016).”

    From Engineered Extracellular Vesicles Loaded With miR-124 Attenuate Cocaine-Mediated Activation of Microglia (2020) · cites this paper as Pitt et al., 2016

  • Dendritic cells and their EVs possess surface adhesion membrane proteins such as integrins, ICAM-1, and MFG-E8 which facilitate effective targeting and docking to recipient cells.

    “These cells and their EVs also possess a variety of surface adhesion membrane proteins such as integrins, immunoglobulin family member ICAM-1, and milk fat globule EGF factor 8 (MFG-E8) which facilitates effective targeting and docking to recipient cells (Pitt et al., 2016).”

    From Engineered Extracellular Vesicles Loaded With miR-124 Attenuate Cocaine-Mediated Activation of Microglia (2020) · cites this paper as Pitt et al., 2016

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 71

  1. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22. · DOI
  2. Chen DS, Mellman I. Oncology meets immu- nology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. · DOI · Paper page
  3. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422. · DOI · Paper page
  4. Pitt JM, et al. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol. 2014;193(3):1006-1011. · DOI
  5. Zhang B, Yin Y, Lai RC, Lim SK. Immunothera- peutic potential of extracellular vesicles. Front Immunol. 2014;5:518.
  6. Gabrilovich DI, Ciernik IF, Carbone DP. Den- dritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 1996;170(1):101-110. · DOI
  7. Zijlstra C, Stoorvogel W. Prostasomes as a source of diagnostic biomarkers for prostate cancer. J Clin Invest. 2016;126(4):1144-1151. · DOI
  8. Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versa- tile roles of extracellular vesicles in cancer. J Clin Invest. 2016;126(4):1163-1172. · DOI
  9. Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest. 2016;126(4):1216-1223. · DOI
  10. Thery C, Ostrowski M, Segura E. Membrane ves- icles as conveyors of immune responses. Nat Rev Immunol. 2009;9(8):581-593. · DOI
  11. Harding CV, Heuser JE, Stahl PD. Exosomes: looking back three decades and into the future. J Cell Biol. 2013;200(4):367-371. · DOI
  12. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14(3):195-208. · DOI · Paper page
  13. Thery C, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166(12):7309-7318. · DOI
  14. Thery C, et al. Molecular characterization of den- dritic cell-derived exosomes. Selective accumu- lation of the heat shock protein hsc73. J Cell Biol. 1999;147(3):599-610. · DOI
  15. Zitvogel L, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4(5):594-600. · DOI
  16. Tamura Y, et al. Heat-shock proteins as endoge- nous ligands building a bridge between innate and adaptive immunity. Immunotherapy. 2012;4(8):841-852. · DOI
  17. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659. · DOI · Paper page
  18. Zhang J, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Pro- teomics Bioinformatics. 2015;13(1):17-24. · DOI
  19. Montecalvo A, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012;119(3):756-766. · DOI · Paper page
  20. Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of peripheral human T cells detected by ELISPOT. Eur J Immu- nol. 2006;36(7):1772-1781. · DOI
  21. Utsugi-Kobukai S, Fujimaki H, Hotta C, Nakazawa M, Minami M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived den- dritic cells. Immunol Lett. 2003;89(2-3):125-131.
  22. Muntasell A, Berger AC, Roche PA. T cell- induced secretion of MHC class II-peptide complexes on B cell exosomes. EMBO J. 2007;26(19):4263-4272. · DOI
  23. Montecalvo A, et al. Exosomes as a short-range mechanism to spread alloantigen between den- dritic cells during T cell allorecognition. J Immu- nol. 2008;180(5):3081-3090. · DOI
  24. Vincent-Schneider H, et al. Exosomes bearing HLA-DR1 molecules need dendritic cells to effi- ciently stimulate specific T cells. Int Immunol. 2002;14(7):713-722. · DOI
  25. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S. Indirect activation of naive CD4 + T cells by dendritic cell-derived exosomes. Nat Immunol. 2002;3(12):1156-1162. · DOI
  26. Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/ peptide complexes to dendritic cells. J Immunol. 2004;172(4):2126-2136. · DOI · Paper page
  27. Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8 + T-cell activation after viral infection. Nature. 2011;471(7340):629-632. · DOI
  28. Viaud S, et al. Updated technology to produce highly immunogenic dendritic cell-derived exo- somes of clinical grade: a critical role of interfer- on-γ. J Immunother. 2011;34(1):65-75. · DOI
  29. Segura E, Amigorena S, Thery C. Mature den- dritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis. 2005;35(2):89-93. · DOI
  30. Segura E, et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood. 2005;106(1):216-223. · DOI
  31. Mallegol J, et al. T84-intestinal epithelial exo- somes bear MHC class II/peptide complexes potentiating antigen presentation by dendritic cells. Gastroenterology. 2007;132(5):1866-1876. · DOI
  32. Nakayama M. Antigen presentation by MHC- dressed cells. Front Immunol. 2014;5:672.
  33. Romagnoli GG, Zelante BB, Toniolo PA, Migliori IK, Barbuto JA. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by con- verting tumor cells into immunogenic targets. Front Immunol. 2014;5:692.
  34. Escudier B, et al. Vaccination of metastatic mel- anoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3(1):10. · DOI
  35. Morse MA, et al. A phase I study of dexosome immunotherapy in patients with advanced non- small cell lung cancer. J Transl Med. 2005;3(1):9. · DOI
  36. Besse B, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line che- motherapy in NSCLC [published online ahead of print February 2, 2016]. Oncoimmunology. doi:10. 1080/2162402X.2015.1071008. · DOI
  37. Dai S, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 2008;16(4):782-790. · DOI
  38. Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011;2011:842849.
  39. Viaud S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and prolifer- ation: a role for NKG2D ligands and IL-15Ralpha. PLoS One. 2009;4(3):e4942. · DOI
  40. Simhadri VR, et al. Dendritic cells release HLA-B-associated transcript-3 positive exo- somes to regulate natural killer function. PLoS One. 2008;3(10):e3377. · DOI
  41. Pogge von Strandmann E, et al. Human leu- kocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immu- nity. 2007;27(6):965-974. · DOI
  42. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer- Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunol- ogy. 2012;1(7):1074-1083. · DOI
  43. Viaud S, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res. 2010;70(4):1281-1285. · DOI
  44. Taieb J, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006;176(5):2722-2729. · DOI
  45. Viaud S, et al. The intestinal microbiota mod- ulates the anticancer immune effects of cyclo- phosphamide. Science. 2013;342(6161):971-976. · DOI · Paper page
  46. Ghiringhelli F, et al. Metronomic cyclo- phosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage can- cer patients. Cancer Immunol Immunother. 2007;56(5):641-648. · DOI
  47. Kamper N, Franken S, Temme S, Koch S, Bieber T, Koch N. gamma-Interferon-regulated chaper- one governs human lymphocyte antigen class II expression. FASEB J. 2012;26(1):104-116. · DOI
  48. Kreiter S, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692-696. · DOI · Paper page
  49. Germain RN, et al. Making friends in out-of-the- way places: how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol Rev. 2008;221:163-181. · DOI
  50. Schreiber RD, Old LJ, Smyth MJ. Cancer immu- noediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570. · DOI · Paper page
  51. Naslund TI, Gehrmann U, Qazi KR, Karlsson MC, Gabrielsson S. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitu- mor immunity. J Immunol. 2013;190(6):2712-2719. · DOI
  52. Qazi KR, Gehrmann U, Domange Jordo E, Karlsson MC, Gabrielsson S. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood. 2009;113(12):2673-2683. · DOI
  53. Chaput N, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lympho- cytes leading to tumor rejection. J Immunol. 2004;172(4):2137-2146. · DOI
  54. Sobo-Vujanovic A, Munich S, Vujanovic NL. Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells. Cell Immunol. 2014;289(1-2):119-127.
  55. Dreux M, et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe. 2012;12(4):558-570. · DOI
  56. Melo SA, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707-721. · DOI
  57. Ghiringhelli F, et al. CD4 + CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunother- apy of established tumors to be curative. Eur J Immunol. 2004;34(2):336-344. · DOI
  58. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metro- nomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 2003;63(23):8408-8413.
  59. Vacchelli E, et al. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoim- munology. 2014;3(1):e27878.
  60. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72. · DOI · Paper page
  61. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and tar- geted anticancer therapies: reinstating immuno- surveillance. Immunity. 2013;39(1):74-88. · DOI
  62. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treat- ment of hematological cancers. Curr Opin Mol Ther. 2010;12(6):724-733.
  63. Benson DM Jr, et al. IPH2101, a novel anti-inhib- itory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118(24):6387-6391. · DOI
  64. Marie-Cardine A, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014;74(21):6060-6070. · DOI
  65. Semeraro M, et al. Clinical impact of the NKp30/ B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med. 2015;7(283):283ra55. · DOI
  66. Rusakiewicz S, et al. Immune infiltrates are prog- nostic factors in localized gastrointestinal stro- mal tumors. Cancer Res. 2013;73(12):3499-3510. · DOI
  67. Remark R, et al. Characteristics and clinical impacts of the immune environments in colorec- tal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res. 2013;19(15):4079-4091. · DOI
  68. Esser J, et al. Exosomes from human macro- phages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration. J Allergy Clin Immunol. 2010;126(5):1032-1040. · DOI
  69. Bajenoff M, et al. Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. J Exp Med. 2006;203(3):619-631. · DOI
  70. Saunderson SC, Dunn AC, Crocker PR, McLellan AD. CD169 mediates the capture of exosomes in spleen and lymph node. Blood. 2014;123(2):208-216. · DOI
  71. Wiklander OP, et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015;4:26316.

Cited by

Sorted by citations

Authors
Pitt, J. M., André, F., Amigorena, S., Soria, J.-C., Eggermont, A., Kroemer, G., & Zitvogel, L.
Venue
Journal of Clinical Investigation
Publisher
American Society for Clinical Investigation
Published
2016-04-01
Volume
126
Issue
4
Pages
1224-1232
ISSN
  • 0021-9738
  • 1558-8238
DOI
10.1172/jci81137
Cited by
583
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review